Amyotrophic Lateral Sclerosis (ALS)

ALS: Control for Laughing/Crying Outbursts

The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its experimental drug Zenvia.

Drug Offers Control for Laughing/Crying Outbursts

The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its experimental drug Zenvia.




Iplex on Hold

The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the foreseeable future, and that it intends to analyze the available data on Iplex for ALS and type 1 myotonic dystrophy (MMD1, or DM1) before deciding whether to proceed with development of the drug for either dise

Iplex on Hold

The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the foreseeable future, and that it intends to analyze the available data on Iplex for ALS and type 1 myotonic dystrophy (MMD1, or DM1)

ALS TDI Update

On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who register. (See Research Update Q209.)

ALS TDI Update

On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who register. (See Research Update Q209.)

Through the Pipeline

On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who register. (See Research Update Q209.)

Iplex on Hold

ALS: Riding for Augie

Many fundraising events for Augie’s Quest (MDA’s aggressive ALS research initiative) tend to be glamorous galas attracting high-profile socialites to genteel settings.

There was nothing genteel about the fundraiser that began June 20 as part of Race Across America (RAAM). It’s one of the toughest endurance events in the world. Cyclists – usually 250 or so, solo or in teams – race 3,000 miles from Oceanside, Calif., to Annapolis, Md. Four-person teams typically cover that distance in five to eight days of nightmarish physical challenge.

ALS: Riding for Augie

Many fundraising events for Augie’s Quest (MDA’s aggressive ALS research initiative) tend to be glamorous galas attracting high-profile socialites to genteel settings.

There was nothing genteel about the fundraiser that began June 20 as part of Race Across America (RAAM). It’s one of the toughest endurance events in the world. Cyclists – usually 250 or so, solo or in teams – race 3,000 miles from Oceanside, Calif., to Annapolis, Md. Four-person teams typically cover that distance in five to eight days of nightmarish physical challenge.

Pages